Tradestie Institutional Equity Comparison Engine

CRESW vs ACAD โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ACAD Overall Edge

ACAD Captures Institutional Edge (3โ€“1 Pillars ยท 10โ€“0 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Acadia Pharmaceuticals Inc. (ACAD) driven by superior Valuation, Growth & Margin, Momentum & Technical while CRESW counters with relative strength in Options & Structure. Fundamentally, CRESW trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus ACAD at 15.8x Forward P/E and 10.2% operating margin (+22.8% YoY). In options structure, CRESW sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against ACAD sits in BREAKDOWN (6th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner ACAD
CRESW N/M vs ACAD 15.8x Fwd P/E
Growth & Margin Winner ACAD
Op Margin N/A vs 10.2% ยท YoY N/A vs +22.8%
Momentum & Technical Winner ACAD
1Y -97.3% vs -25.9% ยท 52W Pos 2% vs 8%
Options & Structure Winner CRESW
UNCLASSIFIED (N/A IV) vs BREAKDOWN (6th %ile IV)
CRESW NASDAQ
Cresud S.A.C.I.F. y A. Warrant
Institutional Equity
$0.03
+1953.33% 1D
Market Cap N/A
1M Return -97.59%
1Y Return -97.3%
Forward P/E N/M
Unified AI Score
43.5 / 100 HOLD
Tech 40.0 Fund 48.0 Flow 50.0 Mom 55.0
ACAD NASDAQ
Acadia Pharmaceuticals Inc.
Pharmaceutical Preparations
$17.11
-2.73% 1D
Market Cap $3.0B
1M Return -15.76%
1Y Return -25.93%
Forward P/E 15.8x
Unified AI Score
44.8 / 100 HOLD
Tech 38.0 Fund 54.0 Flow 67.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CRESW -97.3% ACAD -25.93% Spread: +94.92 pp (ACAD Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
CRESW TTM Op. Margin: N/A ACAD TTM Op. Margin: 10.2%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CRESW vs ACAD. Trailing 12-month operating profitability (CRESW N/A vs ACAD 10.2%) and valuation multiples (CRESW N/M vs ACAD 15.8x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CRESW (0) vs ACAD (10)
Institutional Metric CRESW ACAD Criterion Row Winner
Market Capitalization Scale N/A $3.0B Larger Scale ACAD
Trailing P/E Ratio Valuation N/M 8.3x Lower Multiple ACAD
Forward P/E Ratio Valuation N/M 15.8x Lower Multiple ACAD
Revenue Growth (YoY) Growth N/A +22.8% Higher Growth ACAD
Operating Margin (TTM) Profitability N/A 10.2% Higher Margin ACAD
Net Profit Margin Profitability N/A 30.1% Higher Margin ACAD
Return on Equity (ROE) Capital Efficiency N/A 31.4% Higher ROE ACAD
52-Week Range Position Momentum 2% ($0โ€“$2) 8% ($16โ€“$31) Stronger Trend ACAD
Beta / 30D Volatility Risk Regime 23.08ฮฒ ยท 7022% Vol 0.15ฮฒ ยท 90% Vol Lower Realized Risk ACAD
Unified Institutional Score Composite Signal 43.5 / 100 (HOLD) 44.8 / 100 (HOLD) Higher Composite ACAD

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CRESW vs ACAD Buy Guide
CRESW UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CRESW Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ACAD BREAKDOWN
62d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 6th %ile
IV Regime Compressed (<25th %ile)
Live ACAD Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CRESW nor ACAD registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.